SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02955407

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Genetic Predisposition for Reduced Back Muscle Strength and Back Muscle Endurance in Patients With Chronic Non-specific Low Back Pain

Patients with inflammatory back pain were shown to differ from healthy controls in genotype of the Angiotensin-converting enzyme (ACE), which regulates vasoconstriction/-dilatation. The aim of this study is to investigate whether genetic reduction of muscle perfusion might be a pathophysiological pathway of how genes influence chronic non-specific low back pain (LBP).

NCT02955407 Low Back Pain
MeSH:Back Pain Low Back Pain Disease Susceptibility Genetic Predisposition to Disease
HPO:Back pain Low back pain

1 Interventions

Name: no intervention

Description: observational case-control study
Type: Other
Group Labels: 2

Controls without low back pain Low back pain patients

Primary Outcomes

Measure: Polymorphism ACE Gene

Time: baseline

Measure: Polymorphism Tenascin Gene

Time: baseline

Secondary Outcomes

Measure: Back muscle endurance in Sorensen test

Time: baseline

Time Perspective: Cross-Sectional


There is one SNP


1 rs2104772

- Anti-adhesive extracellular matrix protein Tenascin-C: gene polymorphism rs2104772 The goals of this study are to investigate whether these genotypes correlate with 1) endurance of back muscles, 2) comorbidities such as asthma and diabetes and 3) the risk for LBP as assessed by a LBP-classification tool.

HPO Nodes